Dr PeiQing Zhang
Strategic Technology Partnership Leader CGT, APAC · Pall Corporation
Peiqing Zhang is the Strategic Technology Partnership Leader Gene Therapy at Pall Corporation, responsible for technical engagement with customers and the gene therapy community across Asia Pacific. Peiqing has over 15 years of experience in biotech research, development, and commercial manufacturing. Prior to joining Pall, he held various roles in manufacturing science and technology, analytical development, and CMC management at Novartis in Singapore, and Transcenta in China. Before moving to the biopharmaceutical industry, he was with A*STAR-Singapore’s Bioprocessing Technology Institute and was an Adjunct Assistant Professor at National University of Singapore (NUS). Peiqing obtained his PhD from NUS. He has published more than 20 peer-reviewed papers in biology and biotechnology and is a frequent speaker in international conferences.
Professor Takashi Okada
Professor, Division of Molecular and Medical Genetics, University of Tokyo
Takashi Okada is a clinician-scientist with 30 years of gene and cell therapy experience spanning R&D, clinical medicine, and bioprocessing. He is a professor as well as a director of the Center for Gene and Cell Therapy of the Institute of Medical Science, the University of Tokyo. In 2021, he was re-elected as a vice chairman of the Japan Society of Gene and Cell Therapy. He is also a project sub leader of the Manufacturing Technology Association of Biologics, a Japanese technology research association aiming to establish an industrial base for next-generation gene therapeutics manufacturing technology that meet international standards. He holds MD and PhD.
Dr Clive Glover
General Manager, Gene Therapy, Pall Corporation
Dr. Clive Glover leads Palls Corporation’s cell and gene therapy business where he has been responsible for driving significant growth of Pall’s portfolio for both viral and non-viral delivery of genomic medicine. Previously he was responsible for driving product development efforts around cell therapy at GE Healthcare and has also held positions in marketing and product management at STEMCELL Technologies. Clive holds a PhD in Genetics from the University of British Columbia.
Dr Brian Mullan
Chief Technical Officer, Yposkesi
Brian Mulan joined Yposkesi as Chief Technical Officer in 2020. With over 20 years’ experience working with large multinational companies, including big pharma, Brian has held leadership roles in late phase process development, product launch, commercial supply, process optimization and troubleshooting, and post-approval change management in multiple global markets for therapeutic monoclonal antibodies. He spent the last eight years at Novartis, where he held posts as head of manufacturing science and technology and as a global technical project leader. Between 2008 and 2012, he was process tech transfer lead at Eli Lilly. Prior to that, he worked at Centocor Biologics for nearly three years and Sanofi-Aventis for close to four years. He holds a PhD in Viral Genetics from University College Cork obtained in 2001 and an MBA from the Open University Business School in 2011. He conducted industrial post-doctoral work in gene therapy vectors – Adenoviral and Adeno-Associated Virus (AAV) at Sanofi-Aventis.
Dr Thomas Yuan
Chairman and CEO, TFBS Bioscience
Before founding TFBS in 2016, Dr. Yuan was Vice-President of Development Center of Biotechnology (DCB) in Taiwan, responsible for drug discovery and development. During his 12-year tenure at DCB, Dr. Yuan had leadership roles over various research activities from drug design, assay development, pharmacology, to preclinical development. Prior to joining DCB, Dr. Yuan assumed research positions in the HCV Group at Roche Pharmaceutical in Palo Alto, and in the Gene Therapy Division of Berlex Bioscience in Richmond, California. Dr. Yuan has completed his academic training as a postdoctoral fellow at University of Texas, Medical Branch in Galveston, after obtaining a doctorate degree in Biochemistry from University of Pennsylvania.
About Pall Corporation
Pall Corporation, headquartered in Port Washington, New York, is a global supplier of filtration, separations and purification products. Total revenues for fiscal year 2014 were $2.8 billion, with $103 million spent on R&D. Pall Corporation's business is split into two broad groups: Life Sciences and Industrial.
For more information, visit https://www.pall.com/.